1. Baile CA, Mc Lauglin CL, Della-Fera MA. Cholecystokinin and opioid peptides in control of food intake. Physiol Rev 1986;66:172-234.

2. Benfield P, Heel RC, Lewis SP. Fluoxetine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in depressive illness. Drugs 1996;32:481-508.

3. Blundell JE, Hill AJ. Dexfenfluramine and appetite in humans. Int J Obesity 1992;16 Suppl 3:S51-S59.

4. Blundell JE, Lawton CL. Serotonin and dietary fat intake: effect of dexfenfluramine. Metabolism 1995;44 Suppl.2:33-37.

5. Borsini F, Bendotti C, Aleotti A, Samanin R, Garattini S. d-Fenfluramine and d-norfenfluramine reduce food intake by acting on different serotonin mechanisms in the rat brain. Pharmacol Res Comm 1982;14:671-678.

6. Brauer LH, Johanson CE, Schuster CR, Rothman RB, de Wit H. Evaluation of phentermine and fenfluramine alone and in combination in normal healthy volunteers. Neuropsychopharmacology 1996;14:233-241.

7. Bray GA. et al. Sibutramine–dose response and long term efficacy in weight loss, a double blind study. Int J Obesity 1994;18 Suppl 2:60.

8. Breum L, Pedersen JK, Ahlstrom F, Frimodi-Moller J. Comparison of an ephedrine/caffeine combination and dexfenfluramine in the treatment of obesity: a double-blind multi-centre trial in general practice. Int J Obesity 1994;18:99-103.

9. Bross R, Hoffer LJ. Fluoxetine increases resting energy expenditure and basal body temperature in humans. Am J Clin Nutr 1995;61:1020-1025.

10. Brownell KD, Rodin J. The dieting maelstrom. Is it possible and advisable to lose weight?. Am Psychol 1994;49:781-791.

11. Caccia S, Anelli M, Ferrarese A, Fracasso C, Garattini S. Single and multiple-dose kinetics of d-fenfluramine in rats given anorectic and toxic doses. Xenobiotica 1992;22:217-226.

12. Caccia S, Anelli M, Ferrarese A, Fracasso C, Garattini S. The role of d-norfenfluramine in the indole-depleting effect of d-fenfluramine in the rat. Eur J Pharmacol 1993;233:71-77.

13. Campbell B, Dard-Brunelle B, Caccia S. The use of pharmacokinetics in the assessment of dexfenfluramine safety. In: Nicolaidis S, ed. Obesity management and ReduxTM. San Diego: Academic Press, 1997;65-80.

14. Campfield LA, Smith FJ, Guisez Y, Devos R, Burm P. Recombinant mouse OB protein: evidence for a peripheral signal linking adiposity and central neural networks. Science 1995;269:546-549.

15. Carruba MO, Zambotti F, Vicentini L, Picotti GB, Mantegazza P. Pharmacology and biochemical profile of a new anorectic drug: mazindol. In: Garattini S, Samanin R, eds. Central mechanisms of anorectic drugs. New York: Raven Press, 1978:145-164.

16. Cheymol G, Weissenburger J, Poirier JM, Gellee C. The pharmacokinetics of dexfenfluramine in obese and non-obese subjects. Br J Clin Pharmacol 1995;39:684-687.

17. Cincotta AH, Meier AH. Bromocriptine (Ergoset) reduces body weight and improves glucose tolerance in obese subjects. Diabetes Care 1996;6:667-670.

18. Connolly HM, Crary JL, McGoon MD, et al. Valvular heart disease associated with fenfluramine-phentermine. N Engl J Med 1997:337;581-588.

19. Culpeper N. The English physician enlarged or the herbal. (1653)

20. Curzon G. Serotonin and eating disorders. In: Langer SZ, et al. eds. Serotonin receptor subtypes: Pharmacological significance and clinical implications. Basel: Karger, 1992;112-128.

21. Curzon G, Gibson EL, Oluyomi AO. Appetite suppression by commonly used drugs depends on 5-HT receptors but not on 5-HT availability. Trends Pharmacol Sci 1997;18:21-25.

22. Daly PA, Krieger DR, Dulloo AG, Young JB, Landsberg L. Ephedrine, caffeine and aspirin: safety and efficacy for treatment of human obesity. Int J Obesity 1993;17 Suppl 1:S73-S78.

23. Datla KP, Curzon G. The effect of d-fenfluramine on brain regional 5-hydroxytryptamine and 5-hydroxyindoleacetic acid concentrations in male and female rats. Eur J Pharmacol 1997;333:27-31.

24. Davis R, Faulds D. Dexfenfluramine. An updated review of its therapeutic use in the management of obesity. Drugs 1996;52:696-724.

25. Dietz WH. Pharmacotherapy for childhood obesity? Maybe for some. Obesity Res 1994;2:54-55.

26. Dourish CT. Multiple serotonin receptors: opportunities for new treatments for obesity. Obesity Res 1995;3 suppl 4:449S-462S.

27. Drent ML, Larsson I, William-Olsson T, et al. Orlistat (RO 18-0647), a lipase inhibitor, in the treatment of human obesity. Int J Obesity 1995;18:221-226.

28. Drent ML, Zelissen PMJ, Koppeschaar HPF, et al. The effect of dexfenfluramine on eating habits in a Dutch ambulatory android overweight population with an overconsumption of snacks. Int J Obesity 1995;19:299-304.

29. Dryden S, Frankish HM, Wang Q, Pickvance L, Williams G. The serotonergic agent fluoxetine reduces neuropeptide Y secretion in the hypothalamus of lean and obese rats. Neuroscience 1996;72:557-566.

30. Erickson JC, Hollopeter G, Palmiter RD. Attenuation of the obesity syndrome of ob/ob mice by the loss of neuropeptide Y. Science 1996;274:1704-1707.

31. Foltin RW, Kelly TH, Fischman MW. The effect of d-amphetamine on food intake of humans living in a residential laboratory. Appetite 1990;15:33-45.

32. Garattini S. Mechanisms of actions of anorectic drugs. In: Meyer S, Chaouloff F, Gilbert J-C, Rolland Y, eds. Medicaments et comportements alimentaires. Paris: Masson, 1988;1-24.

33. Garrow JS, Webster JD. Effects on weight and metabolic rate of obese women on a 3.4 MJ (800 Kcal) diet. Lancet 1989;1:1429-1431.

34. Gerald C , Walker MW, Criscione L, et al. A receptor subtype involved in neuropeptide- Y-induced food intake. Nature 1996;382:168-171.

35. Gibson EL, Kennedy AJ, Curzon G. d-Fenfluramine and d-norfenfluramine-induced hypophagia: differential mechanisms and involvement of postsynaptic 5-HT receptors. Eur J Pharmacol 1993;242:83-90.

36. Goldstein DJ. Beneficial effects of modest weight loss. Int J Obesity 1992;6:397-415.

37. Goldstein DJ, Rampey AH, Enas GG, Potvin JH, Fludzinski LA, Levine LR. Fluoxetine: A randomized clinical trial in the treatment of obesity. Int J Obesity 1994;8:129-135.

38. Graham DJ, Green L. Further cases of valvular heart disease associated with fenfluramine-phentermine. N Engl J Med 1997;337:635.

39. Grignaschi G, Sironi F, Samanin R. The 5-HT1B receptor mediates the effect of d- fenfluramine on eating caused by intra-hypothalamic injection of neuropeptide Y. Eur J Pharmacol 1995;274:221-224.

40. Guy-Grand B. Clinical studies with dexfenfluramine: from past to future. Obesity Res 1995;3 Suppl 4:491S-496S.

41. Guy-Grand B, Apfelbaum M, Crepaldi G, Griess A, Lefebvre P, Turner P. International trial of long-term dexfenfluramine in obesity. Lancet 1989;2:1142-1144.

42. Hale J. The civilization of Europe in the Renaissance. London: Fontana Press, 1994: 503.

43. Halford JCG, Blundell JE. Metergoline antagonizes fluoxetine-induced suppression of food-intake but not changes in the behavioral satiety sequence. Pharmacol Biochem Behav 1996;54:745-751.

44. Halford JCG, Blundell JE. The 5-HT1B receptor agonist CP-94,153 reduces food intake and preserves the behavioral satiety sequence. Physiol Behav 1996;60:933-939.

45. James WPT. A public health approach to the problem of obesity. Int J Obesity 1995;19 Suppl 3:S37-S45.

46. Jones SP, Smith IG, Kelly F, Gray JA. Long-term weight loss with sibutramine. Int J Obesity 1995;19 Suppl 2:41.

47. Kelly F, Wade AG, Jones SP, Johnson SG. Sibutramine hydrochloride vs. dexfenfluramine: weight loss in obese subjects. Int J Obesity 1994;18 Suppl 2:61.

48. Kennett GA. 5-HT1C receptors and their therapeutic relevance. Curr Opin Invest Drugs 1993;2:317-362.

49. Kissebah AH, Krakower GR. Regional adiposity and morbidity. Physiol Rev 1994;74:761-811.

50. Kuczmarski RJ, Flegal KM, Campbell SM, Johnson CL. Increasing prevalence of overweight among US adults. JAMA 1994;272:205-211.

51. Kushner R. The treatment of obesity. A call for prudence and professionalism. Arch Int Med 1997;157:602-604.

52. Lancet Correspondence on dexfenfluramine and neurotoxicity. 1992;339:359-361.

53. Largis EE, Burns MG, Muenkel HA, Dolan JA, Claus TH. Antidiabetic and antiobesity effects of a highly selective beta 3-adrenoreceptor agonist (CL 316,243). Drug Dev Res 1994;32:69-76.

54. Lasagna L. The pharmacotherapy of obesity. In: Meltzer HY, ed. Psychopharmacology: The third generation of progress. New York: Raven Press, 1987;1281-1284.

55. Laudignon N, Rebuffe-Scrive M. Overview of the safety data. In: Nicolaidis S, ed. Obesity management and ReduxTM. San Diego: Academic Press, 1997;105-111.

56. Lean MEJ. Sibutramine—a review of clinical efficacy. Int J Obesity 1997;21 Suppl 1:S30-S36.

57. Leibowitz SF. Brain peptides and obesity: pharmacological treatment. Obesity Res 1995;3 Suppl 4:573S-589S.

58. Leibowitz SF, Kim T. Impact of a galanin antagonist on exogenous galanin and natural patterns of fat ingestion. Brain Res 1992;599:148-152.

59. Leibowitz SF, Weiss GF, Shor-Posner G. Hypothalamic serotonin: pharmacological, biochemical and behavioral analyses of its feeding-suppressive action. Clin Neuropharmacol 1988;11 suppl 1:S51-S71.

60. Lesses MF, Myerson A. Benzedrine sulphate as an aid in the treatment of obesity. N Engl J Med 1938;218:119-124.

61. Lew R, Weisenberg B, Vosmer G, Seiden S. Combined phentermine/fenfluramine administration enhances depletion of serotonin from central terminal fields. Synapse 1997;26:36-45

62. Locke KW, Levesque TR, Nicholson KL, Balster RL. Dexfenfluramine lacks amphetamine-like abuse potential. Progr Neuropsychopharmacol Biol Psychiatry 1996;20:1019-1035.

63. Lovenberg TW, Baron BM, de Lecea L, et al. A novel adenylcyclase-activating serotonin receptor (5-HT7) implicated in the regulation of mammalian circadian rhythms. Neuron 1993;11:449-458.

64. Marbury TC, Angelo JE, Gulley RM, Krosnick A, Sugimoto, DH, Zellner SR. A placebo-controlled dose-response study of dexfenfluramine in the treatment of obesity. Curr Ther Res 1996;57:663-674.

65. Melia AT, Koss-Twardy SG, Zhi J. The effect of orlistat, an inhibitor of dietary fat absorption, on the absorption of vitamins A and E in healthy volunteers. J Clin Pharmacol 1996;36:647-653.

66. Mennini T, Bizzi A, Caccia S, et al. Comparative studies on the anorectic activity of d- fenfluramine in mice rats and guinea pigs. Naunyn-Schmiedebergs Arch Pharmacol 1991;343:483-490.

67. Meyerowitz W, Jaramillo JDC. Sertraline treatment and weight loss. Curr Ther Res 1994;55:1176-1181.

68. Munro JF, Mac Cuish AC, Wilson EM, Duncan LJP. Comparison of continuous and intermittent anorectic therapy in obesity. Br Med J 1968;1:352-354.

69. National Task Force on the Prevention and Treatment of Obesity. Long-term pharmacotherapy in the management of obesity. JAMA 1996;276:1907-1915.

70. Neill JC, Cooper SJ. Evidence that d-fenfluramine anorexia is mediated by 5-HT1, receptors. Psychopharmacology 1989;97:213-218.

71. New Engl J Med Correspondence. Appetite-suppressant drugs and primary pulmonary hypertension. 1996;336:510-513.

72. Nicolaidis S. Obesity management and ReduxTM. San Diego: Academic Press, 1997;1-126.

73. O'Connor HT, Richman RM, Steinbeck KS, Caterson ID. Dexfenfluramine treatment of obesity: a double-blind trial with post trial follow up. Int J Obesity 1995;19:181-189.

74. Oluyomi AO, Datla KP, Curzon G. Effects of d-fenfluramine on feeding and hypothalamic 5-hydroxytryptamine and dopamine in male and female rats. Eur J Pharmacol 1994;255:175-183.

75. Oluyomi AO, Gibson EL, Barnfield AMC, Curzon G. d-Fenfluramine and d-norfenfluramine hypophagias do not require increased hypothalamic 5-hydroxytryptamine release. Eur J Pharmacol 1994;264:111-115.

76. Pelleymounter MA, Cullen MJ, Baker MB, et al. Effects of the obese gene product on body weight regulation in ob/ob mice. Science 1995;269:540-543.

77. Prescott-Clark B, Primatesta P. Health survey for England, 1995. London: HMSO, 1995.

78. Raiteri M, Bonanno G, Vallebuona F. In vitro and in vivo effects of d-fenfluramine: no apparent relation between 5-hydroxytryptamine release and hypophagia. J Pharm Exp Ther 1995;273:643-649.

79. Royal College of Physicians. Overweight and obese patients. Principles of management with particular reference to the use of drugs. 1997;1-24.

80. Samanin R, Neill, KC, Grignaschi G, Padura IM, Bizzi A, Garattini S. Role of 5-HT receptors in the effect of d-fenfluramine on gastric emptying and feeding behaviour as examined in the runway test. Eur J Pharmacol 1991;197:69-73.

81. Sandage BW. Overview of the clinical data. In: Nicolaidis S, ed. Obesity management and ReduxTM. San Diego: Academic Press, 1997;83-86.

82. Schwartz MW, Peskind E, Boyko EJ, Porte D. Cerebrospinal fluid leptin levels: relationships to plasma levels and to adiposity in humans. Nature Medicine 1996;2:589-593.

83. Silverstone T. Appetite suppressants: a review. Drugs 1992;43:820-836.

84. Smith FJ, Campfield LA, Moschera JA, Ballon PS, Burn P. Feeding inhibition by neuropeptide Y. Nature 1996;382:307.

85. Snow JT, Harris MB. An analysis of weight and diet content in five women's interest magazines. J Obes Weight Regul 1986;5:195-214.

86. Steel JM, Munro JF, Duncan LJP. A comparative trial of different regimes of fenfluramine and phentermine in obesity. Practitioner 1973;211:232-236.

87. Stock MJ. Sibutramine: a review of the pharmacology of a novel anti-obesity agent. Int J Obesity 1997;21 Suppl 1:S25-S29

88. Strosberg AD, Pietri-Rouxel F. Function and regulation of the b3-adrenoreceptor.Trends Pharmacol Sci 1996;17:373-381.

89. Turton MD, O'Shea D, Gunn I, et al. A role for glucagon-like peptide-1 in the central regulation of feeding. Nature 1996;379:69-72.

90. Van Gaal LF, Vansant GA, Steijaert MC, De Leeuw IH. Effects of dexfenfluramine on resting metabolic rate and thermogenesis in premenopausal obese women during therapeutic weight reduction. Metabolism 1995;44 Suppl 2:42-45.

91. Wadden TA, Bartlett SJ, Foster GD, et al Sertraline and relapse prevention training following very low calorie diet: a controlled clinical trial. Obes Res 1995;3:549-557.

92. Weintraub M, ed. Long-term weight control: the National Heart, Lung and Blood Institute funded multimodal intervention study. Clin Pharmacol Ther 1992;51:581-585.

93. Weintraub M, Rubio A, Golik A, Byrne L, Scheinbaum ML. Sibutramine in weight control: a dose-ranging efficacy study. Clin Pharmacol Ther 1991;50:330-337.

94. Wiseman CV, Gray JJ, Mosimann JE, Ahrens AH. Cultural expectations of thinness in women: an update. Int J Eating Disord 1992;11:85-89.

95. Wurtman J, Wurtman R, Reynolds S, Tsay R, Chew B, et al. Fenfluramine suppresses snack intake among carbohydrate cravers but not among non-carbohydrate cravers. Int J Eating Disord 1987;6:689-699.

96. Yen TT, Fuller RW. Preclinical pharmacology of fluoxetine, a serotonergic drug for weight loss. Am J Clin Nutr 1992;55:177S-180S.

97. Zhi J, Melia AT, Koss-Twardy SG, Arora S, Patel IH. The effect of orlistat, an inhibitor of dietary fat absorption, on the pharmacokinetics of beta-carotene in healthy volunteers. J Clin Pharmacol 1996;36:152-159.

Back to Chapter